Published in J Virol on November 01, 1995
Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A (2002) 4.66
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J (2003) 4.19
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol (1997) 2.28
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol (2006) 1.87
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79
The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med (1998) 1.59
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol (2000) 1.55
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med (1997) 1.55
Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol (1998) 1.49
Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol (2010) 1.41
Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol (2001) 1.40
Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord (2005) 1.40
The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors. J Exp Med (2001) 1.38
Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol (1999) 1.36
CD4+-T-cell and CD20+-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J Virol (1998) 1.36
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol (1999) 1.25
Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol (2008) 1.14
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol (2007) 1.03
Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol (1999) 0.98
Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J Virol (2011) 0.96
Replication properties of clade A/C chimeric feline immunodeficiency viruses and evaluation of infection kinetics in the domestic cat. J Virol (2008) 0.94
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A (2016) 0.93
Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5α. Virology (2010) 0.91
Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. J Virol (2002) 0.88
Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol (2014) 0.88
The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2013) 0.86
Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol (2000) 0.84
Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection. Vaccine (2010) 0.83
Macaques as model hosts for studies of HIV-1 infection. Front Microbiol (2013) 0.83
Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques. Clin Dev Immunol (2012) 0.82
Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. PLoS One (2011) 0.81
Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate. J Med Primatol (2011) 0.77
The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes. J Virol (2003) 0.75
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Fluorescence detection in automated DNA sequence analysis. Nature (1986) 12.53
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (1985) 12.08
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol (1991) 4.82
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
The simian immunodeficiency viruses. Annu Rev Immunol (1990) 4.32
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol (1991) 3.99
Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94
Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A (1993) 3.63
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05
Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol (1993) 2.65
Replication and pathogenesis of the AIDS virus. J Acquir Immune Defic Syndr (1988) 2.50
Envelope sequences of two new United States HIV-1 isolates. Virology (1988) 2.44
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. J Virol (1992) 2.05
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J Gen Virol (1992) 1.76
Vaginal transmission of human immunodeficiency virus (HIV) to a chimpanzee. J Infect Dis (1986) 1.38
Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology (1991) 1.35
Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J Virol (1994) 1.25
HIV-related lentiviruses of nonhuman primates. AIDS Res Hum Retroviruses (1989) 1.14
Antigenic variation of molecularly cloned SIVmac239 during persistent infection in a rhesus macaque. Virology (1993) 1.10
Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. Vaccine (1988) 1.09
Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function. J Virol (1993) 1.07
Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology (1993) 0.96
Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. Virology (1994) 0.78
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science (1984) 9.14
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
The isolation and characterization of the human suppressor inducer T cell subset. J Immunol (1985) 6.69
Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 5.47
Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet (1998) 5.46
Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24
The isolation and characterization of the human helper inducer T cell subset. J Immunol (1985) 5.21
Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol (1986) 4.48
Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
Childhood leukaemia in the West Berkshire and Basingstoke and North Hampshire District Health Authorities in relation to nuclear establishments in the vicinity. Br Med J (Clin Res Ed) (1987) 4.17
A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med (1989) 4.16
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05
Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94
Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature (1987) 3.77
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol (1993) 3.27
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18
Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol (1999) 3.17
Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 3.13
Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988) 2.97
In vitro growth characteristics of simian T-lymphotropic virus type III. Proc Natl Acad Sci U S A (1985) 2.90
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol (1991) 2.77
Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol (1988) 2.68
Mortality in Barrett's esophagus: three decades of experience at a single center. Endoscopy (2012) 2.67
Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A (1987) 2.66
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66
Subcellular localization of the human immunodeficiency virus trans-acting art gene product. J Virol (1988) 2.64
Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A (1989) 2.64
A study of the quality and duration of survival following resection, endoscopic intubation and surgical intubation in oesophageal carcinoma. Br J Surg (1982) 2.52
Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization. J Virol (1986) 2.52
Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes. J Virol (1986) 2.50
The effect of thyro-parathyreoidectomy on the heart and circulation: Part II. Action of guanidin on the heart of the frog. J Physiol (1920) 2.33
Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax (2008) 2.32
Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol (1997) 2.28
Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci U S A (1985) 2.25
Should NHS patients be allowed to contribute extra money to their care? BMJ (2001) 2.22
A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. Science (1984) 2.22
Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol (1992) 2.21
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Acquired immunodeficiency syndrome in a colony of macaque monkeys. Proc Natl Acad Sci U S A (1983) 2.17
OBSERVATIONS ON THE CAUSE OF RICKETS. Br Med J (1918) 2.06
1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol (1989) 2.04
Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science (1986) 2.03
A tripartite HIV-1 tat-env-rev fusion protein. EMBO J (1990) 2.01
The Shatin community mental health survey in Hong Kong. II. Major findings. Arch Gen Psychiatry (1993) 1.99
JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology (1999) 1.97
Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer (1988) 1.96
Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proc Natl Acad Sci U S A (1989) 1.96
Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol (1989) 1.91
Methanogenesis, fires and the regulation of atmospheric oxygen. Biosystems (1978) 1.88
The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques. J Immunol (1990) 1.87
Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett (1996) 1.87
Childhood leukaemia in West Berkshire. Lancet (1985) 1.76
Cell kinetics in flat (avillous) mucosa of the human small intestine. Gut (1973) 1.76
Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci U S A (1998) 1.74
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol (1997) 1.72
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol (1990) 1.70
T lymphocyte surface antigens in primates. Eur J Immunol (1983) 1.68
Evolution of the MHC class I genes of a New World primate from ancestral homologues of human non-classical genes. Nature (1990) 1.68
Trans activation of the bovine leukemia virus long terminal repeat in BLV-infected cells. Science (1985) 1.67
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag. J Immunol (1992) 1.65
T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med (1995) 1.61
Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax (1997) 1.60